The Clinicopathological and Prognostic Implications of FoxP3(+) Regulatory T Cells in Patients with Colorectal Cancer: A Meta-Analysis

FoxP3(+)调节性T细胞在结直肠癌患者中的临床病理学和预后意义:一项荟萃分析

阅读:1

Abstract

Background and Objective: Forkhead box P3 (FoxP3) is known as the specific marker for regulatory T lymphocytes (Tregs), which are responsible for self-tolerance and disturb the antitumor immunity. However, the prognostic implication of tumor-infiltrating FoxP3(+) Tregs in patients with colorectal cancer (CRC) still remains controversial. The aim of this present study was to investigate the prognostic role of FoxP3(+) Tregs in CRC through meta-analysis. Methods: PubMed, Embase and Web of Science were searched for relevant articles up to December 12, 2016. Pooled hazard ratio (HR) and 95% confidence interval (CI) were calculated to explore the prognostic value of FoxP3(+) Tregs in CRC. Odds ratio (OR) was calculated to investigate the correlation between FoxP3(+) Tregs and pathological parameters. Results: A total of 18 studies comprising 3,627 patients with CRC were enrolled in our meta-analysis. The combined HR for FoxP3(+) Tregs on cancer-specific survival was 0.70 (95% CI = 0.62-0.80, P < 0.001). High FoxP3(+) Tregs level was also associated with favorable prognosis on overall survival (HR = 0.76, 95% CI = 0.58-1.01, P = 0.058), with P-value very close to the statistical threshold. Yet, there was no correlation between FoxP3(+) Tregs infiltration and disease-free survival (HR = 0.83, 95% CI = 0.63-1.09, P = 0.182). Moreover, FoxP3(+) Tregs infiltration was significantly correlated with pT stage (OR = 0.50, 95% CI = 0.39-0.65, P < 0.001), tumor grade (OR = 0.77, 95% CI = 0.61-0.98, P = 0.032), lymphatic invasion (OR = 0.25, 95% CI = 0.07-0.89, P = 0.033) and vascular invasion (OR = 0.67, 95% CI = 0.52-0.86, P = 0.001). Conclusion: The present meta-analysis suggests that high FoxP3(+) Tregs infiltration is inclined to indicate favorable prognosis and is associated with the pathogenesis of CRC. Immunotherapy targeting Tregs in patients with CRC should be further investigated.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。